Ester Lovsin Barle, PhD

Takeda
Global Head of Product Sustainability and Stewardship
Ester Lovsin Barle is a global leader in product sustainability and stewardship, with over 28 years of work experience, including 16 years in the pharmaceutical industry. She holds a DVM, MSc, PhD, and MScTox degrees, and has extensive expertise in toxicology, occupational health, and environmental sustainability. She is currently the Global Head of Product Sustainability and Stewardship at Takeda, where she oversees the implementation of Takeda’s global environmental sustainability goals and product compliance and risk programs. She also represents Takeda in external forums and collaborations on product stewardship and environmental sustainability topics. Ester is the chair of ISPE Sustainability CoP.

Related Articles

water-piping-750px
iSpeak Blog
Why Water Circularity Matters to Pharma Now More Than Ever
Water sits at the center of human health, ecosystem stability, and industrial resilience, yet the world is entering an era of unprecedented water stress. According to the United Nations (UN), 2.2 billion people lack access to safely managed drinking water. If no corrective action is taken, an estimated 5.7 billion people may experience water scarcity for at least one month each year. Water...
1125_PE_ND_Pruess
Features
Expanding Extended Producer Responsibility: Challenges and Opportunities
Pharmaceuticals are not only regulated by traditional pharmaceutical legislation but are also increasingly influenced by related environmental and stewardship laws. Extended producer responsibility (EPR) is reshaping the pharmaceutical industry with regulatory burdens, challenges, and strategic opportunities.
Technology and Innovation
iSpeak Blog
Future-Proofing Pharma and Personal Care: How Life Cycle Assessments and Carbon Footprinting Drive Real Change
Already in the 1980s and 1990s, environmental labelling programs emerged as a way to guide consumers toward greener choices. These third-party “seal-of-approval” systems—like the European Communities Eco-labelling Program (Regulation (EC) No 66/2010 – EUR-Lex), the Nordic Countries program, and the national programs of Canada, France, Germany, Austria, the Netherlands, Singapore, New Zealand, and...
ecologist-taking-samples-water-with-test-tube-from-city-river-determine-level-contamination-pollution
iSpeak Blog
Navigating the PFAS Challenge in Pharma

Per- and polyfluoroalkyl substances (PFAS) have emerged as a major concern in the pharmaceutical industry and beyond. Restricting their use is heavily debated. On the one hand, these “forever chemicals” can pose environmental and human health risks. On the other hand, their unique physical and chemical properties can make them important for pharma and ultimately for helping to enable access to...

Challenges for Net Zero Carbon Pharmaceutical Manufacturing
Features
Challenges for Net Zero Carbon Pharmaceutical Manufacturing

The scientific community accepts that greenhouse gas (GHG) emissions cause global warming and climate change.Intergovernmental Panel on Climate Change (IPCC). “Sixth Assessment Report: Climate Change 2021: The Physical Science Basis.” Finalized 9 August 2021.

Sustainability Definitions for the Pharmaceutical Industry
Features
Sustainability Definitions for the Pharmaceutical Industry

While financial investment in novel therapies provides patients with new treatment options and improved quality of care, the pharmaceutical industry also recognizes its responsibility to transition toward more sustainable development, manufacturing, and stewardship of medicines throughout their life cycle.